Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial
Background. A new agent, potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer advantages over conventional H. pylori eradication therapies. We aimed to compare the eradication rate between VPZ-based treatment and PPI-based one. Methods. This randomized...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2017/4385161 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550309780520960 |
|---|---|
| author | Masafumi Maruyama Naoki Tanaka Daisuke Kubota Masayuki Miyajima Takefumi Kimura Koujiro Tokutake Ryujiro Imai Toru Fujisawa Hiromitsu Mori Yoshiaki Matsuda Shuichi Wada Akira Horiuchi Kendo Kiyosawa |
| author_facet | Masafumi Maruyama Naoki Tanaka Daisuke Kubota Masayuki Miyajima Takefumi Kimura Koujiro Tokutake Ryujiro Imai Toru Fujisawa Hiromitsu Mori Yoshiaki Matsuda Shuichi Wada Akira Horiuchi Kendo Kiyosawa |
| author_sort | Masafumi Maruyama |
| collection | DOAJ |
| description | Background. A new agent, potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer advantages over conventional H. pylori eradication therapies. We aimed to compare the eradication rate between VPZ-based treatment and PPI-based one. Methods. This randomized controlled trial was designed to assign 141 patients with H. pylori-positive gastritis to VPZ group (VPZ 20 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days) or PPI group (rabeprazole 20 mg or lansoprazole 30 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days). Primary endpoints were eradication rates and adverse events. Results. Seventy of 72 patients in VPZ group and 63 of 69 patients in PPI group completed the treatment after 7 days. The eradication rate was significantly higher in VPZ group than PPI group by intention-to-treat analysis (95.8% versus 69.6%, P=0.00003, 95% confidence interval [CI] 88.3-99.1% versus 57.3-80.1%) and per-protocol analysis (95.7% versus 71.4%, P=0.0002, 95% CI 88.0-99.1% versus 58.7-82.1%). The incidence of adverse events was not different between the groups (26.3% in VPZ group versus 37.7% in PPI group, P=0.15). Conclusion. VPZ-based regimen is more useful than that PPI-based regimen as a first-line H. pylori eradication therapy. |
| format | Article |
| id | doaj-art-ddc2930cbd21400aafd3e60f9c0a4192 |
| institution | Kabale University |
| issn | 2291-2789 2291-2797 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-ddc2930cbd21400aafd3e60f9c0a41922025-02-03T06:07:13ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27892291-27972017-01-01201710.1155/2017/43851614385161Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled TrialMasafumi Maruyama0Naoki Tanaka1Daisuke Kubota2Masayuki Miyajima3Takefumi Kimura4Koujiro Tokutake5Ryujiro Imai6Toru Fujisawa7Hiromitsu Mori8Yoshiaki Matsuda9Shuichi Wada10Akira Horiuchi11Kendo Kiyosawa12Department of Gastroenterology, Nagano Red Cross Hospital, Nagano, JapanDepartment of Metabolic Regulation, Shinshu University Graduate School of Medicine, Matsumoto, JapanDepartment of Gastroenterology, Nagano Red Cross Hospital, Nagano, JapanDepartment of Gastroenterology, Nagano Red Cross Hospital, Nagano, JapanDepartment of Gastroenterology, Nagano Red Cross Hospital, Nagano, JapanDepartment of Gastroenterology, Nagano Red Cross Hospital, Nagano, JapanDepartment of Gastroenterology, Nagano Red Cross Hospital, Nagano, JapanDepartment of Gastroenterology, Nagano Red Cross Hospital, Nagano, JapanDepartment of Gastroenterology, Nagano Red Cross Hospital, Nagano, JapanDepartment of Gastroenterology, Nagano Red Cross Hospital, Nagano, JapanDepartment of Gastroenterology, Nagano Red Cross Hospital, Nagano, JapanDigestive Disease Center, Showa Inan General Hospital, Komagane, JapanDepartment of Gastroenterology, Aizawa Hospital, Matsumoto, JapanBackground. A new agent, potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer advantages over conventional H. pylori eradication therapies. We aimed to compare the eradication rate between VPZ-based treatment and PPI-based one. Methods. This randomized controlled trial was designed to assign 141 patients with H. pylori-positive gastritis to VPZ group (VPZ 20 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days) or PPI group (rabeprazole 20 mg or lansoprazole 30 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days). Primary endpoints were eradication rates and adverse events. Results. Seventy of 72 patients in VPZ group and 63 of 69 patients in PPI group completed the treatment after 7 days. The eradication rate was significantly higher in VPZ group than PPI group by intention-to-treat analysis (95.8% versus 69.6%, P=0.00003, 95% confidence interval [CI] 88.3-99.1% versus 57.3-80.1%) and per-protocol analysis (95.7% versus 71.4%, P=0.0002, 95% CI 88.0-99.1% versus 58.7-82.1%). The incidence of adverse events was not different between the groups (26.3% in VPZ group versus 37.7% in PPI group, P=0.15). Conclusion. VPZ-based regimen is more useful than that PPI-based regimen as a first-line H. pylori eradication therapy.http://dx.doi.org/10.1155/2017/4385161 |
| spellingShingle | Masafumi Maruyama Naoki Tanaka Daisuke Kubota Masayuki Miyajima Takefumi Kimura Koujiro Tokutake Ryujiro Imai Toru Fujisawa Hiromitsu Mori Yoshiaki Matsuda Shuichi Wada Akira Horiuchi Kendo Kiyosawa Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial Canadian Journal of Gastroenterology and Hepatology |
| title | Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial |
| title_full | Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial |
| title_fullStr | Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial |
| title_full_unstemmed | Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial |
| title_short | Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial |
| title_sort | vonoprazan based regimen is more useful than ppi based one as a first line helicobacter pylori eradication a randomized controlled trial |
| url | http://dx.doi.org/10.1155/2017/4385161 |
| work_keys_str_mv | AT masafumimaruyama vonoprazanbasedregimenismoreusefulthanppibasedoneasafirstlinehelicobacterpylorieradicationarandomizedcontrolledtrial AT naokitanaka vonoprazanbasedregimenismoreusefulthanppibasedoneasafirstlinehelicobacterpylorieradicationarandomizedcontrolledtrial AT daisukekubota vonoprazanbasedregimenismoreusefulthanppibasedoneasafirstlinehelicobacterpylorieradicationarandomizedcontrolledtrial AT masayukimiyajima vonoprazanbasedregimenismoreusefulthanppibasedoneasafirstlinehelicobacterpylorieradicationarandomizedcontrolledtrial AT takefumikimura vonoprazanbasedregimenismoreusefulthanppibasedoneasafirstlinehelicobacterpylorieradicationarandomizedcontrolledtrial AT koujirotokutake vonoprazanbasedregimenismoreusefulthanppibasedoneasafirstlinehelicobacterpylorieradicationarandomizedcontrolledtrial AT ryujiroimai vonoprazanbasedregimenismoreusefulthanppibasedoneasafirstlinehelicobacterpylorieradicationarandomizedcontrolledtrial AT torufujisawa vonoprazanbasedregimenismoreusefulthanppibasedoneasafirstlinehelicobacterpylorieradicationarandomizedcontrolledtrial AT hiromitsumori vonoprazanbasedregimenismoreusefulthanppibasedoneasafirstlinehelicobacterpylorieradicationarandomizedcontrolledtrial AT yoshiakimatsuda vonoprazanbasedregimenismoreusefulthanppibasedoneasafirstlinehelicobacterpylorieradicationarandomizedcontrolledtrial AT shuichiwada vonoprazanbasedregimenismoreusefulthanppibasedoneasafirstlinehelicobacterpylorieradicationarandomizedcontrolledtrial AT akirahoriuchi vonoprazanbasedregimenismoreusefulthanppibasedoneasafirstlinehelicobacterpylorieradicationarandomizedcontrolledtrial AT kendokiyosawa vonoprazanbasedregimenismoreusefulthanppibasedoneasafirstlinehelicobacterpylorieradicationarandomizedcontrolledtrial |